Skip to content
mapperlab
← Dashboard
Stock

LFCR

LIFECORE BIOMEDICAL, INC.
Latest close $4.383 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
3
27 funds tracked
Ever held
7
Current + past
New this quarter
0
Exited this quarter
3

Marquee-fund ownership over time

Aug 9, 2024Nov 13, 2024Aug 14, 2025May 15, 2026
Now
3

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Millennium Management$6.71$4.38-35%
AQR Capital Management$7.42$4.38-41%
Point72 Asset Management$7.16$4.38-39%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors 2× in & out→ $4.40-34%
Two Sigma Investments→ $4.40-39%
D.E. Shaw→ $4.40-39%
Renaissance Technologies→ $7.09+42%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at LIFECORE BIOMEDICAL, INC. DE. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
9
Filings · last 90d
10
Total on file
519
Recent SEC buffer
Most recent
Jun 8, 2026

30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 519 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · LIFECORE BIOMEDICAL, INC.

Annual figures sourced directly from LIFECORE BIOMEDICAL, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$75.52M
FY2025+500%+ YoY
Net income
-$17.96M
FY2025-500%+ YoY
EPS (diluted)
$-0.5400
FY2025-500%+ YoY
Free cash flow(?)
$3.63M
FY2025+127% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for LIFECORE BIOMEDICAL, INC. \DE\ — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ1 2026Q2 2026$7.16$4.40-39%
D.E. ShawQ1 2026Q2 2026$7.16$4.40-39%
Point72 Asset ManagementQ1 2026open$7.16$4.38-39%
AQR Capital ManagementQ3 2025open$7.42$4.38-41%
Citadel AdvisorsQ2 2025Q2 2026$6.71$4.40-34%
Millennium ManagementQ2 2025open$6.71$4.38-35%
Citadel AdvisorsQ3 2024Q4 2024$5.81$6.68+15%
Renaissance TechnologiesQ3 2024Q4 2024$5.01$7.09+42%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.